HIV Infections Clinical Trial
Official title:
HIV Prevention Programs for Middle School Students
This study will develop and evaluate a school-based HIV, STD, and pregnancy prevention program for 7th and 8th grade middle school students.
The purpose of this study is to develop and evaluate a school-based HIV, STD, and pregnancy
prevention program for 7th and 8th grade middle school students using a
randomized-controlled intervention trial. The intervention program consists of a
classroom-based curriculum and an interactive CD-ROM. Ten middle schools were recruited to
participate in this intervention trial. Five middle schools were randomized to the
intervention group; and five middle schools were randomized to the control group. The study
is also developing a model for obtaining community support for the development of HIV, STD
and pregnancy prevention programs for middle school youth.
The primary hypothesis to be tested is: Students attending middle schools who receive a
multi-component HIV, STD, pregnancy prevention intervention will postpone sexual activity or
reduce levels of current sexual activity relative to those in the comparison condition. The
major dependent variables are proportion of students that are sexually active, and the
proportion initiating sexual intercourse. Intentions to engage in sexual activity, number of
times of unprotected sexual intercourse, and number of sexual partners will also be
examined. Secondary hypotheses will examine the effect of the multi-component HIV, STD, and
pregnancy prevention intervention on the student's knowledge, self-efficacy, attitudes,
perceived norms, barriers, and communication with parents.
The specific aims of this project are to:
1. Develop a model for obtaining community-based support for HIV, STD, and pregnancy
prevention interventions for middle school students.
2. Adapt a tested, school-based, HIV, STD, and pregnancy prevention curriculum for middle
school students using qualitative data from the target population, parents, and
community representatives.
3. Develop an interactive CD-ROM-based tailored HIV, STD and pregnancy prevention
intervention to provide individualized learning opportunities for middle school
students.
4. Evaluate the effect of the multi-component intervention (classroom curriculum and
CD-ROM intervention) on sexual behavior outcomes (proportion of students who initiate
sexual intercourse, proportion of currently sexually active students having unprotected
sexual intercourse, number of sexual partners, and intentions to have sexual
intercourse) among middle school students.
5. Evaluate the effect of the multi-component intervention on student impact variables
such as knowledge, self-efficacy, attitudes, barriers, and perceived norms related to
sexual risk-taking behavior and academic achievement among middle school students.
6. Disseminate findings to the scientific community, school districts, and community
agencies.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |